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Abstract: Charcot-Marie-Tooth disease (CMT) is a common inherited peripheral neuropathy affecting
up to 1 in 1214 of the general population with more than 60 nuclear genes implicated in its
pathogenesis. Traditional molecular diagnostic pathways based on relative prevalence and clinical
phenotyping are limited by long turnaround time, population-specific prevalence of causative
variants and inability to assess multiple co-existing variants. In this study, a CMT gene panel
comprising 27 genes was used to uncover the pathogenic mutations in two index patients. The first
patient is a 15-year-old boy, born of consanguineous parents, who has had frequent trips and falls
since infancy, and was later found to have inverted champagne bottle appearance of bilateral legs
and foot drop. His elder sister is similarly affected. The second patient is a 37-year-old woman
referred for pre-pregnancy genetic diagnosis. During early adulthood, she developed progressive
lower limb weakness, difficulties in tip-toe walking and thinning of calf muscles. Both patients are
clinically compatible with CMT, have undergone multiple genetic testings and have not previously
received a definitive genetic diagnosis. Patients 1 and 2 were found to have pathogenic homozygous
HSPB1:NM_001540:c.250G>A (p.G84R) variant and heterozygous GDAP1:NM_018972:c.358C>T
(p.R120W) variant, respectively. Advantages and limitations of the current approach are discussed.
Keywords: Charcot-Marie-Tooth disease (CMT); hereditary motor and sensory neuropathy (HMSN);
pathogenic variants; gene panel; next-generation sequencing (NGS)
1. Introduction
Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy
estimated to affect 1 in 1214 of the general population [1]. Over 60 nuclear genes have been implicated
in the pathogenesis of this group of disorders, and the genetic cause of about 50% of clinically diagnosed
CMT remains unidentified [2]. The inheritance of this group of disorders is variable, and cases with
mutations that are autosomal dominant [3,4], autosomal recessive [5,6], X-linked dominant [7], X-linked
recessive [8] and de novo [9] have all been described. Even within the same causative gene, CMT
inheritance has been reported to vary in a site-specific manner [10]. Furthermore, clinical severity and
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prognosis of CMT also depends on the presence of modifying mutations [11]. Identification of the exact
or most probable underlying genetic mutation is therefore of importance in the clinical management,
genetic and reproductive counselling of patients diagnosed to have CMT.
In diseases with multiple causative genes such as CMT, diagnostic algorithms based on clinical
phenotyping and known prevalence of genetic defect has been preferred [12]. While large-scale
genotyping studies had elucidated more detailed genetic epidemiology of CMT and led to continuous
refinement of such algorithms [13], the concurrent advancement of genomic technologies has
more recently allowed the simultaneous interrogation of multiple gene targets with comparable
cost-effectiveness [14–16]. The advantage of this alternative approach is multifold: first, there
is potential cost-savings in labour, reagents and possibly a reduction in total turnaround time in
the diagnostic laboratory; second, it allows a more confident, broad-based genetic diagnosis to be
established as known disease genes are tested with less a priori assumptions regarding the prevalence
of specific genetic mutations and genetic aetiology of the disease; third, and perhaps most importantly,
it provides information for elucidating the roles of co-existing, disease-modifying and cumulative
pathogenic effect of multiple variants [17].
In this study, a commercial CMT gene panel comprising 27 known disease-causing genes (Table 1)
was used to screen for mutations in autosomal dominant, autosomal recessive, X-linked forms of
CMT, and hereditary motor and sensory neuropathy. Next-generation sequencing with high coverage
(≥100×) was used for detection of SNPs (single nucleotide polymorphisms) and indel variants for two
clinically diagnosed CMT patients who had previously undergone conventional, step-wise genetic
testing but have not received a positive genetic diagnosis. Gene-panel sequencing findings were
validated and interpreted in the context of family and clinical history. Finally, iterative in silico
simulation was used to suggest a clinically useful range of sequencing coverage for detecting CMT
mutations by gene-panel sequencing experiments in the clinical laboratory.
Table 1. Charcot-Marie-Tooth disease (CMT) 27-gene panel used in the current study.
Gene CMT Phenotype Inheritance Chromosome Location
KIF1B CMT 2A1 AD 1p36.22
MFN2 CMT 2A2A & 2A2B AD, AR 1p36.22
YARS Dominant intermediate CMT(DI-CMT) type C AD 1p35.1
LMNA CMT 2B1 AR 1q22
MPZ DI-CMT type D, CMT 1B, 2I & 2J AD 1q23.3
RAB7A CMT 2B AD 3q21.3
SH3TC2 CMT 4C AR 5q32
FIG4 CMT 4J AR 6q21
GARS CMT 2D AD 7p14.3
HSPB1 CMT 2F AD 7q11.23
NEFL CMT 1F & 2E AD, AR 8p21.2
GDAP1 Recessive intermediate CMTtype A, CMT 2K & 4A AD, AR 8p21.11
NDRG1 CMT 4D AR 8q24.22
EGR2 CMT 1D AD 10q21.3
SBF2 CMT 4B2 AR 11p15.4
MTMR2 CMT 4B1 AR 11q21
FGD4 CMT 4H AR 12p11.21
TRPV4 Hereditary motor and sensoryneuropathy (HMSN) IIc AD 12q24.11
HSPB8 CMT 2L AD 12q24.23
LITAF CMT 1C AD 16p13.13
AARS CMT 2N AD 16q22.1
PMP22 CMT 1A & 1E AD 17p12
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Table 1. Cont.
Gene CMT Phenotype Inheritance Chromosome Location
DNM2 DI-CMT type B, CMT 2M AD 19p13.2
PRX CMT 4F AR 19q13.2
MED25 CMT 2B2 AR 19q13.33
GJB1 X-linked dominant CMT type 1 XLD Xq13.1
PRPS1 X-lined recessive CMT type 5 XLR Xq22.3
2. Results
2.1. Case Report
2.1.1. Case 1
Patient 1 (II-2, Figure 1a) is a 15-year-old boy who tripped and fell frequently since infancy.
He fractured his ankle at 10 years old and started to walk with an awkward gait after his plaster was
removed. Subsequently, he developed slowly progressive weakness of his lower limbs.
Examination revealed muscle wasting of both distal leg and foot muscles, with inverted
champagne bottle appearance of bilateral legs and foot drop. He walked with a high stepping
gait. Examination of his upper limbs showed mild thenar and hypothenar muscle wasting with
normal power. The peripheral reflexes and sensation were normal. He had no facial weakness, ptosis
or respiratory problem. Nerve conduction studies (NCS) showed absent compound muscle action
potential upon supra-maximal stimulation of both peroneal and tibial nerves. The nerve conduction
velocities of the median and ulnar nerves and the sensory nerve action potential of both sural nerves
were normal. The result was suggestive of axonal degenerative motor neuropathy. Previous genetic
tests showed no duplication of PMP22 or mutation in GJB1 and MFN2.
The patient’s parents are cousins, and there is also a history of consanguineous marriage in the last
three generations of the family. Upon inquiry, the 17-year-old sister of Patient 1 was noted to be clumsy
since infancy and could only walk independently from 18 months onwards. She developed frequent
falls since 14 years of age but she remained ambulatory. Examination revealed muscle wasting of
distal lower limb muscles and bilateral foot drop. She also walked with a high stepping gait. Nerve
conduction studies also revealed similar findings to that in Patient 1. No previous genetic test was
performed in this sibling.
2.1.2. Case 2
Patient 2 (II-1, Figure 1b) was referred to us for pre-pregnancy genetic diagnosis and counselling
at the age of 37. She enjoyed good past health until the age of 18, when she was noticed to have some
difficulties in walking. During her twenties, the weakness progressed further and she developed
difficulties in tip-toe walking and running. Her family member also noticed thinning of her calves.
There was no upper limb or bulbar involvement. One of her paternal aunts developed similar walking
problems at the age of 45. The patient’s parents are asymptomatic.
On examination, there was muscle wasting over the anterior and posterior compartment of
bilateral lower limbs. Hammer toe and pes cavus were noted. The lower limb reflexes were absent
despite reinforcement. There was decrease in distal muscle power over bilateral ankles to grade four
minus (Medical Research Council (MRC) scale) while the proximal muscle power of her lower limbs
was largely preserved. There was no cerebellar sign. Gait examination revealed a high-stepping gait
and the patient was unable to perform tip-toe walking. The upper limb examinations were normal.
NCS showed a mild decrease in amplitude in bilateral peroneal nerves. NCS on Patient 2’s mother only
showed diabetes-related nerve conduction changes; and that performed on her father was essentially
normal. NCS on her clinically affected paternal aunt was compatible with axonal type motor and
sensory neuropathies over bilateral upper and lower limbs. Previous genetic tests of the proband
showed no duplication of PMP22.
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Figure 1. (a) Pedigree showing the autosomal recessive inheritance in Case 1 with selected
electrophoretograms from Sanger sequencing in the cascade screening. Unaffected siblings II-3 to II-5
are all negative for the HSPB1:NM_001540:c.250G>A (p.G84R) variant. Both parents (I-1 and I-2) are
heterozygous for the variant, whereas the proband (II-2) and his affected elder sister (II-1) are both
homozygous for the pathogenic variant; (b) Pedigree showing the autosomal dominant inheritance
in Case 2. The proband (II-1), her father (I-2) and her paternal aunt (I-1) are all heterozygous for
the pathogenic variant GDAP1:NM_018972:c.358C>T (p.R120W), and the proband’s mother (I-3) is
homozygous for the wildtype allele. The phenotype of I-2 may be explained by the incomplete
penetrance of dominant GDAP1 mutations, which is discussed in text. In the figure, filled circles
and squares denote affected females and males, respectively. A central dot in a symbol denotes an
asymptomatic carrier and a line through the symbol denotes a currently asymptomatic carrier who
may later develop the disease. The probands are marked with an arrow and a letter “p”.
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2.2. Identification of Pathogenic Variants
2.2.1. Case 1
A total of 204 variants, comprising 162 SNPs and 42 indels, were called by HaplotypeCaller with
confidence score ≥50. Using wANNOVAR, after filtering by allele frequency to exclude variants
with allele frequency ≥0.05 in the 1000 Genome project and Exome Aggregation Consortium (ExAC)
database, three exonic or splice-site variants remained. MutationTaster identified 209 analysable
alterations (some variants mapped to more than one transcript) and three variants were predicted to
be disease-causing. Only one variant was predicted to be Mendelian disease-causing by KGGSeq (Table 2).
Among the shortlisted variants, only the HSPB1 non-synonymous SNP variant has a homozygous
genotype and is compatible with the autosomal recessive inheritance demonstrated in the pedigree
of the patient; database search with the Human Gene Mutation Database (www.hgmd.cf.ac.uk)
revealed the known mutation CM084860, which has been described in an asymmetrical late onset
form of CMT [10] and demonstrated to cause decreased HSPB1-HSPB6 heterooligomer formation,
hence decreased chaperone activity [18]. The homozygous pathogenic variant in the HSPB1 gene
was confirmed in the patient by bi-directional Sanger sequencing. Cascade testing confirmed the
homozygous HSPB1:NM_001540:c.250G>A (p.G84R) variant in the patient’s symptomatic elder sister
and both parents were found to be heterozygous for the variant; the patient’s three other siblings did
not carry the mutation (Figure 1a).
Table 2. Exonic and splice-site variants shortlisted using wANNOVAR and analysed by MutationTaster
and KGGSeq.
Case Variant Gene (Variant Type)
wANNOVAR (Exome
Aggregation Consortium
(ExAC) Overall Minor Allele
Frequency (MAF))
MutationTaster
Prediction (Prediction
Probability, Pcorrect)
KGGSeq Prediction
(Disease-Casual
Probability, Pdisease)
1
chr1:156109095_156109095delA
LMNA:NM_170707:cD
NA.2405_2405delA
Lamin A/C
(Heterozygous 3′ UTR
indel in a poly-A stretch) *
(excluded) 1
Disease-causing
(Pcorrect > 0.999)
No prediction 2
chr7:75932279G>A
HSPB1:NM_001540:c.G250A
(p.G84R)
Heat shock protein family
B member 1 (Homozygous
nonsynonymous SNP)
Shortlisted (no ExAC data) Disease-causing(Pcorrect > 0.999)
Disease-causing
(Pdisease = 0.681)
chr11:9861208G>C
SBF2:NM_030962:c.C3292G
(p.L1098V)
SET binding factor 2
(Heterozygous
nonsynonymous SNP)
Shortlisted (MAF = 0.0209) Polymorphism(Pcorrect = 0.054) 3
Non-disease-causing
(Pdisease = 3.46 × 10−4)
chr11:95595177A>G
MTMR2:NM_016156: c.T447C
(p.Y149Y)
Myotubularin related
protein 2 (Heterozygous
synonymous SNP)
Shortlisted
(MAF = 2.527 × 10−5, all from
South Asian data in ExAC)
Disease-causing
(Pcorrect = 1)
No prediction 2
2
chr1:10342522G>A
KIF1B:NM_015074:c.G1227A
(p.T409T)
Kinesin family member 1B
(Heterozygous
synonymous SNP)
Shortlisted (MAF = 0.0328) Polymorphism(Pcorrect = 2.98 × 10−17) 3 (filtered)
4
chr1:10397567A>G
KIF1B:NM_015074:c.A3260G
(p.Y1087C)
Kinesin family member 1B
(Heterozygous
synonymous SNP)
Shortlisted (MAF = 0.0325) Polymorphism(Pcorrect = 5.41 × 10−11) 3
Non-disease-causing
(Pdisease = 0.039)
chr1:156109095_156109095delA
LMNA: NM_170707:cDNA.2405_
2405delA
Lamin A/C
(Heterozygous 3′ UTR
indel in a poly-A stretch) *
(excluded) 1
Disease-causing
(Pcorrect > 0.999)
No prediction 2
chr8:75272419C>T
GDAP1:NM_018972:c.C358T
(p.R120W)
Ganglioside-induced
differentiation-associated
protein 1 (Heterozygous
nonsynonymous SNP)
Shortlisted (no ExAC data) Disease-causing(Pcorrect > 0.999)
Disease-causing
(Pdisease = 0.500)
chr11:9990017G>A
SBF2:NM_030962:c.C1471T
(p.L491F)
SET binding factor 2
(Heterozygous
nonsynonymous SNP)
Shortlisted (no ExAC data) Disease-causing(Pcorrect > 0.999)
Non-disease-causing
(Pdisease = 0.044)
1 The shortlisting by allele frequency was limited to “exome summary results” per wANNOVAR settings; 2 KGGSeq
pathogenicity prediction for non-synonymous variants is based on a logistic regression model combining scores
from 14 prediction algorithms/models including SIFT (http://sift.jcvi.org/), PolyPhen2 (http://genetics.bwh.
harvard.edu/pph2/) and CADD (http://cadd.gs.washington.edu/), thus no prediction is provided for non-coding
variants; 3 From MutationTaster documentation (http://doro.charite.de/MutationTaster/info/documentation.html),
a prediction probability below 0.5 indicates that the Bayesian classifier gives a different prediction, and in all three
cases the “Polymorphism” prediction was automatically assigned using allele frequency data; 4 KGGSeq filtered the
variants by their maximum frequency among sub-populations nested in the database: in this case, the variant has
an allele frequency of 0.08 in the East Asian population in ExAC and was therefore filtered; * Possibly representing a
sequencing error due to (1) tri-allelic reads noted in manual inspection of alignment and (2) indel situating at end of
a poly-(A) tract.
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2.2.2. Case 2
A total of 193 variants, comprising 160 SNPs and 33 indels, were called by HaplotypeCaller
with confidence score ≥50. Using wANNOVAR with similar filtering criteria as Case 1, four variants
remained. Analysis with MutationTaster identified 199 analysable alterations, and three variants were
predicted to be disease-causing. Again, only one variant was predicted to be Mendelian disease-causing
by KGGSeq (Table 2).
The heterozygous GDAP1:NM_018972:c.358C>T (p.R120W) variant was initially reported as a
mutation in autosomal recessive form of CMT [19], and was later found also in the autosomal dominant
form of the disease [20]. It is also listed in the Human Gene Mutation Database as known mutation
CM032927. The mutation was successfully confirmed in the patient by bi-directional Sanger sequencing.
On cascade screening, the patient’s father (clinically asymptomatic, no definite electrophysiological
features of CMT) and her paternal aunt (affected, compatible electrophysiological changes over bilateral
upper and lower limbs) were both found to harbour the pathogenic GDAP1 variant. The variant was
not detected in the GDAP1 gene of the patient’s mother (Figure 1b). These findings are compatible with
the previously reported incomplete penetrance of the GDAP1 p.R120W substitution in an Ashkenazi
Jew family [21].
2.3. Estimation of Minimal Sequencing Depth for Genetic Diagnosis
With mean target coverage of 213.4× for Case 1 (target coverage ≥2×: 99.09%, ≥10×: 98.64%,
≥50×: 90.98%) and 184.2× for Case 2 (target coverage ≥2×: 99.29%, ≥10×: 98.85%, ≥50×: 89.50%),
random sampling of reads was performed from 100% of reads with 5% decremental steps down to 5%,
with 10 samples at each level of coverage. Using original data as the pseudo-truth set, with decreasing
depth of coverage, the mean proportion of SNPs called decreased from 100% (162.0 ± 0.0) at full
coverage to 71.0% (115.0 ± 6.0) at 5% (10.7×) coverage for Case 1 and 99.7% (159.5 ± 0.5) to 73.8%
(118.0 ± 3.2) for Case 2 (Figure 2a).
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Figure 2. Effect of sequencing coverage on (a) SNP and (b) indel calling. Error bars represent standard
deviation of percentage of SNP and indel recovered at each level of coverage, calculated from 10
replicates. The dashed line (in blue) denotes an arbitrary 95% threshold of the total number of variants
recovered, using the variant calls from the full sequencing data as the pseudo-truth set.
Similarly, the mean proportion of indels called decreased from 99.3% (41.7 ± 0.5) to 27.1%
(11.4 ± 1.7) for Patient 1 and 100% (33.0 ± 0.0) to 26.1% (8.6 ± 1.1) (Figure 2b). Thus, the average
coverage required to correctly call 95% of the SNPs (Csnp95) was determined to be 43× < Csnp95 < 53×
for Case 1 and 55× < Csnp95 < 64× for Case 2. The average coverage required to correctly call 95% of
the indels (Cindel95) was 192× < Cindel95 < 203× for Patient 1 and 156× < Cindel95 < 166× for Patient 2.
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The minimal mean target coverage at which the homozygous variant HSPB1:NM_ 001540:c.250G>A
from Patient 1 could be called from all 10 iterations was 21.3× (10% of original coverage, average
coverage of 5.4× at the SNP site), and that of the heterozygous variant GDAP1:NM_018972:c.358C>T
from Patient 2 was 9.2× (5% of original coverage, average coverage of 16.4× at the SNP site).
3. Discussion
In this study, we report the successful application of targeted gene-panel sequencing in the
genetic diagnosis of two cases of CMT. Because of the large number of genes implicated in this
heterogeneous group of disease, this and other studies [22–25] together highlight the practical
advantage of high-throughput sequencing in rapidly reaching the specific genetic diagnosis over
previously proposed stepwise diagnostic algorithms [26–28]. As illustrated in Case 1, the patient had
undergone screening for PMP22 duplication, mutation of GJB1 and MFN2 and active investigation
for more than two years before the gene-panel method was attempted. It is perhaps less surprising
if the logistics, quality control and accreditation requirements peculiar to a clinical laboratory are
considered: the turn-around time of testing even a single gene is usually more than a few weeks even
in resource-rich countries (https://ghr.nlm.nih.gov/primer/testing/costresults). This is obviously
in stark contrast to many research centres where researchers using flexible workflows can quickly
produce results.
Patients having disease mutations in genes at the distal end of the diagnostic algorithm often
have delayed genetic diagnosis. While the sequential testing of disease genes ranked by prevalence
and clinical picture may result in certain “cost-savings”, it can also mean an unacceptably long
time-to-diagnosis on an individual and community level. In Case 2, the rapid screening role of the gene
panel is well-illustrated: contemplating pregnancy at age of 37, the patient faces an age-dependent
increase in adverse foetal and maternal outcome [29]. Recent studies suggest that a short waiting
time—which is often facilitated by faster test turn-around time—is among the more important factors
to patients attending clinical genetic services [30] and the preference for pre-implantation genetic
diagnosis decreases with a long waiting list even for couples with a high risk of transmitting genetic
disorders to their offspring [31].
While the genetic diagnoses in both cases were successful and relatively straightforward, from
the perspective of a clinical laboratory, we also point out certain limitations and caveats in the
application of the current approach. First, high-quality sequence of adequate coverage is essential
for the successful application of this workflow, yet current technology still mandates a trade-off
between breadth and depth of sequencing. While exome or whole genome data may be acquired
and restricted variant calling be performed to flexibly simulate the effect of a gene panel and extend
analysis into deep non-coding regions as required, the use of a physical gene panel, either by nucleic
acid capture or target amplification, still provides a higher and potentially more even coverage of
the target regions [32]. Statistical or rule-based variant filtering [33–35] and downstream Sanger
sequencing validation may be required unless variant calling is highly confident. As seen from the
down-sampling experiment, although the original coverage achieved is more than two times the 43× to
64× coverage estimated to achieve 95% of the SNP-calling sensitivity, the coverage margin, especially
for indel-calling, can certainly be improved (Figure 2b). It is also possible that further improvement in
sequencing chemistry, coverage depth and variant-calling algorithms may further reduce the number
of “confident” yet spurious variant calls and decrease the workload for manual validation (Table 2;
also see supplementary material II). Additionally, we note that the rarefaction curves presented thereof
are optimistic estimates, since the pseudo-truth set is inherently biased towards SNPs and indels that
are more easily (hence already) called at low coverages using existing pipelines; as such, no attempt
was made to calculate the asymptotic values of total number of SNPs and indels to avoid misleading
conclusions. An alternate approach to reduce this bias would be the cross-validation with alternate
variant detection methods, such as SNP arrays [14], at different levels of sequencing coverage.
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Second, and perhaps more importantly, the genomic alteration leading to the disease that can be
detected by this approach is limited to single-nucleotide variants and small insertions and deletions.
Determination of large insertions and deletions, copy number variations and genomic rearrangements,
even with state-of-the-art analytical software tools [36], is still met with much difficulty especially in
gene-panel assays [37]. As gene duplications and deletions are important mechanisms implicated in
the pathogenesis of CMT, over-reliance on this single modality of molecular diagnostics can lead to
false-negative results.
Preliminary testing for PMP22 (chromosome 17p) duplication had been performed in both
Case 1 and Case 2. Certainly, it may be argued that, due to the prevalence of PMP22 duplication
and deletions, particularly in the more prevalent Type 1 (demyelinating) CMT [2], the preferential
testing of such instead of direct gene-panel screening may be a more practical approach [13].
However, this is complicated by uncertainties in electrophysiological and clinical phenotyping of CMT.
Electrophysiological phenotyping method using nerve conduction velocity [38] has been compromised
not only by significant variability within patient groups with the same mutation [39], but also the
increased recognition of a group of mutations leading to intermediate nerve conduction velocities [40].
As far as clinical phenotyping is concerned, genetically informed analysis of patient cohort comprising
various CMT subtypes also showed marked phenotypic variability within type 1 and type 2 CMT [41].
It is becoming clear that the underlying mutation, instead of electrophysiological, phenotypic or mode
of inheritance, characterize the CMT subtypes [2].
For the two cases described in this study, it is uncertain whether the previous genetic test sequence
would have been altered by the clinical information and electrophysiological tests: despite nerve
conduction velocity findings compatible with type 2 CMT, PMP22 genetic testing, which should have
higher diagnostic yield in type 1 CMT [42], was still performed. In view of such, the early application of
gene-panel sequencing in screening for pathogenic variants, in localities where such technologies and
interpretive expertise are more easily available, could therefore eliminate unnecessary repeated clinical
examinations, electrophysiological studies and surgical biopsies. However, multiplex or massively
parallel sequencing, even if only limited to a panel of known disease genes, has a significant risk of
producing equivocal results, i.e., multiple variants “of unknown significance” [43], especially when the
disease-causing variant is not obvious from initial database search. Clinical correlations and further
investigations, therefore, shall be the logical response to the multitude of hypotheses put forth by the
clinical sequencing experiment.
4. Materials and Methods
4.1. Patients and Human Ethics
Seven members of a family of Pakistan descent (Case 1) and four members of a Han Chinese
family (Case 2) were examined. Peripheral blood was collected from all 11 of them and gene-panel
sequencing was performed for the two probands. The study was reviewed and approved by the
Hong Kong Hospital Authority/Hong Kong East Cluster Institutional Review Board Ethics Committee
(HKEC-2016-047). Written informed consent for genetic testing and participating in the study was
obtained from all subjects or their parents/guardians.
4.2. Gene-Panel and Next-Generation Sequencing
Following genomic DNA extraction from peripheral blood, DNA from targeted regions was
enriched using SeqCap EZ Choice Library (Roche NimbleGen, Madison, WI, USA) with the custom
oligonucleotide library generated against coding exons of 27 CMT disease-related genes (Table 1).
The target-enriched DNA was sequenced by the Illumina HiSeq 2000 sequencing platform (Illumina,
San Diego, CA, USA). The gene-panel capture and sequencing was performed at the BGI Diagnostics
sequencing facilities (BGI, Shenzhen, China).
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4.3. Variant Discovery and Annotation
The paired-end 100 base-pair (bp) reads were mapped onto the UCSC human reference genome
(version hg19) using BWA-MEM (version 0.7.12) [44]. Duplicate reads were removed using Picard Tools
(version 1.94, available from https://github.com/broadinstitute/picard/). After realignment around
indels and quality score recalibration, variant calling was performed using HaplotypeCaller (minimum
Phred-scaled confidence score = 50; limiting to exons listed in Table 1 and their respective 100 bp
upstream and 100 bp downstream regions) [45]. Variant quality score recalibration and hard filtering
were not performed because of the relatively small dataset and the need to maximize sensitivity
in this clinical study. The variant-calling pipeline has been validated using the NA12878 TruSeq
Exome enrichment HiSeq 2500 reads (data available from https://basespace.illumina.com/analyses/
36605989?projectId=25504495) against the USA National Institute of Standards and Technology (NIST)
Genome in a Bottle v3.2.2 (hg19) using Variant Calling Assessment Tool (v3.0) and achieved a single
nucleotide variant (SNV) recall and precision of 96.57% and 99.11%; and indel recall and precision of
89.12% and 92.64% (supplementary material I).
All variants called by the pipeline were subjected to wANNOVAR [46], KGGSeq [47] and
MutationTaster [48] analysis as follows. Variants were processed using wANNOVAR for functional
annotation and to exclude variants not within the exome regions included by wANNOVAR and
those with allele frequency ≥0.05 in 1000 Genome project or ExAC database [46]. Pathogenicity
prediction of nonsynonymous variants was performed using KGGSeq with default quality control
criteria (–gty-qual 20 –gty-dp 4), additional option to predict Mendelian disease-causing and complex
disease-causing variants (–mendel-causing-predict best –db-score dbnsfp –db-gene refgene) and
reporting variants with allele frequency <0.05 in 1000 Genome project and ExAC database (–db-filter
1kg201305,dbsnp138,exac –rare-allele-freq 0.05) [47]. Additionally, the variants were submitted to
MutationTaster for extended pathogenicity detection for synonymous, splice-site and non-coding
region variants [48]. The pathogenic variants shortlisted by MutationTaster were cross-checked
with wANNOVAR exome region annotation and had their reads-mapping inspected manually in
Integrative Genomics Viewer to note unusual patterns of mapping which may indicate sequencing or
mapping errors.
4.4. Pathogenic Variant Validation and Cascade Screening
Bi-directional Sanger sequencing was performed for pathogenic variants identified to validate
and genotype variants, similar to previously described [49]. Briefly, DNA from peripheral blood
was extracted using Qiagen QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany) following
the manufacturer’s instructions and eluted in 100 µL of Tris-EDTA buffer. Target regions were
amplified from extracted genomic DNA by PCR, each 25 µL reaction contains: 12.5 µL AmpliTaq Gold®
360 Master Mix (Applied Biosystems, CA, USA), 1.0 µL 360 GC Enhancer, 25 µM of each of forward
and reverse primers, 20 ng purified genomic DNA and 7.5 µL of PCR-grade water. Amplification
was performed using a stepdown PCR protocol as follows: initial denaturation at 95 ◦C for 10 min,
subsequent denaturation at 95 ◦C for 30 s, annealing for 30 s with 1 ◦C decrement per cycle, from
66 to 56 ◦C for 10 cycles, followed by 30 cycles at 60 ◦C for, extension at 72 ◦C for 1 min, followed
by final extension at 72 ◦C for 10 min. The PCR products were electrophoresed in 2% agarose in
1× TBE buffer electrophoresis, stained with GelStar (Lonza, Basel, Switzerland). Post-PCR clean-up
was performed using EXO-SAP IT® (Affymetrix, CA, USA) according to the manufacturer’s protocol.
Sanger sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, CA, USA) and an ABI 3500 genetic analyzer. Cascade screening for the family members
of the affected probands for the pathogenic mutations identified was similarly performed. For Case
1, both parents and four siblings of the proband (including one symptomatic sibling) were screened
(Figure 1a). For Case 2, both parents and a symptomatic paternal aunt were screened (Figure 1b).
The grandparents and other relatives of both probands could not be reached for the cascade screening.
Int. J. Mol. Sci. 2017, 18, 770 11 of 13
4.5. Down-Sampling Experiment
Rarefaction curves (Figure 2) were used to explore the effect of sequencing depth on variant
discovery. To estimate the sequencing coverage needed for discovering clinically significant
homozygous and heterozygous variants, average depth of coverage of the target genomic regions
was first calculated using CollectHsMetrics command in Picard Tools and a Python script was written
to repeatedly execute HaplotypeCaller with -dfrac values from 1.0 (100% of sequencing reads) with
decrement steps of 0.05, down to 0.05 (5% of sequencing reads). The number of SNP and indel variants
called were plotted against the average coverage with respective standard deviation (n = 10).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/4/770/s1.
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